Literature DB >> 30896596

Comparison of Collapsibility of the Human Upper Airway During Anesthesia and During Sleep.

Kathleen J Maddison1,2, Jennifer H Walsh1,2, Kelly L Shepherd1,2, Chrianna Bharat3,4, Bradley K Lawther5, Peter R Platt5, Peter R Eastwood1,2, David R Hillman1,2.   

Abstract

BACKGROUND: The propensities for the upper airway to collapse during anesthesia and sleep are related, although much of our understanding of this relationship has been inferred from clinical observation and indirect measures such as the apnea-hypopnea index. The aim of this study was to use an identical, rigorous, direct measure of upper airway collapsibility (critical closing pressure of the upper airway) under both conditions to allow the magnitude of upper airway collapsibility in each state to be precisely compared.
METHODS: Ten subjects (8 men and 2 women; mean ± SD: age, 40.4 ± 12.1 years; body mass index, 28.5 ± 4.0 kg/m) were studied. Critical closing pressure of the upper airway was measured in each subject on separate days during (1) propofol anesthesia and (2) sleep.
RESULTS: Critical closing pressure of the upper airway measurements were obtained in all 10 subjects during nonrapid eye movement sleep and, in 4 of these 10 subjects, also during rapid eye movement sleep. Critical closing pressure of the upper airway during anesthesia was linearly related to critical closing pressure of the upper airway during nonrapid eye movement sleep (r = 0.64 [95% CI, 0.02-0.91]; n = 10; P = .046) with a similar tendency in rapid eye movement sleep (r = 0.80 [95% CI, -0.70 to 0.99]; n = 4; P = .200). However, critical closing pressure of the upper airway during anesthesia was systematically greater (indicating increased collapsibility) than during nonrapid eye movement sleep (2.1 ± 2.2 vs -2.0 ± 3.2 cm H2O, respectively, n = 10; within-subject mean difference, 4.1 cm H2O [95% CI, 2.32-5.87]; P < .001) with a similar tendency during rapid eye movement sleep (1.6 ± 2.4 vs -1.9 ± 4.3 cm H2O, respectively, n = 4; unadjusted difference, 3.5 cm H2O [95% CI, -0.95 to 7.96]; P = .087).
CONCLUSIONS: These results demonstrate that the magnitude of upper airway collapsibility during anesthesia and sleep is directly related. However, the upper airway is systematically more collapsible during anesthesia than sleep, suggesting greater vulnerability to upper airway obstruction in the anesthetized state.

Entities:  

Year:  2020        PMID: 30896596     DOI: 10.1213/ANE.0000000000004070

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  4 in total

1.  Relationship between the activity of the genioglossus, other peri-pharyngeal muscles and flow mechanics during wakefulness and sleep in patients with OSA and healthy subjects.

Authors:  Ron Oliven; Guy Cohen; Mostafa Somri; Alan R Schwartz; Arie Oliven
Journal:  Respir Physiol Neurobiol       Date:  2019-12-19       Impact factor: 1.931

Review 2.  Drug-Induced Sleep Endoscopy: Technique, Indications, Tips and Pitfalls.

Authors:  Marina Carrasco-Llatas; Silvia Matarredona-Quiles; Andrea De Vito; Khai Beng Chong; Claudio Vicini
Journal:  Healthcare (Basel)       Date:  2019-07-24

3.  ED50 and ED95 of Propofol Combined with Different Doses of Intravenous Lidocaine for First-Trimester Uterine Aspiration: A Prospective Dose-Finding Study Using Up-and-Down Sequential Allocation Method.

Authors:  Jingwen Zhang; Linglingli Kong; Juan Ni
Journal:  Drug Des Devel Ther       Date:  2022-09-28       Impact factor: 4.319

4.  Canadian Airway Focus Group updated consensus-based recommendations for management of the difficult airway: part 2. Planning and implementing safe management of the patient with an anticipated difficult airway.

Authors:  J Adam Law; Laura V Duggan; Mathieu Asselin; Paul Baker; Edward Crosby; Andrew Downey; Orlando R Hung; George Kovacs; François Lemay; Rudiger Noppens; Matteo Parotto; Roanne Preston; Nick Sowers; Kathryn Sparrow; Timothy P Turkstra; David T Wong; Philip M Jones
Journal:  Can J Anaesth       Date:  2021-06-08       Impact factor: 5.063

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.